Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellectar Biosciences filings document the regulatory record of a Delaware clinical biopharmaceutical company developing cancer therapies through its PDC platform. Current reports furnish quarterly and annual financial results, corporate updates, Regulation FD disclosures, and other events related to iopofosine I 131, CLR 125 and regulatory communications for its oncology programs.
Registration statements and material-event reports describe securities offerings, shelf registration activity, registered direct offerings, private placements, common stock, pre-funded warrants, milestone-based warrants and warrant exercise inducement transactions. The filing record also covers exhibit disclosures, Inline XBRL cover data, incorporation status, securities-law classifications and financing agreements that shape CLRB's public-company capital structure.
Cellectar Biosciences (Nasdaq:CLRB) filed an 8-K to update investors on pipeline progress in connection with a proposed securities offering.
- CLR 125 (Auger I-125): favorable pre-clinical safety, strong uptake in triple-negative breast cancer; Phase 1b dose-finding study planned for 2H 2025.
- CLR 225 (Ac-225 α-emitter): tumor reduction in pancreatic, colorectal and breast models; Phase 1 imaging/dose-escalation study also slated for 2H 2025.
- Both trials depend on new financing.
- Iopofosine CLOVER-WaM Phase 2b in refractory Waldenström macroglobulinemia met its primary endpoint, posting a 58.2% major response rate (vs 20% FDA hurdle) and 83.6% ORR; responses durable with median DOR not reached at 11.4 mo.
Offering proceeds are expected to fund operating expenses and the CLR 125 trial; amount and timing were not disclosed.
Cellectar Biosciences (Nasdaq: CLRB) filed a Form S-1 to raise up to ≈$6.0 million through the sale of up to 755,667 Class A Units (or the same number of Class B Units). Each unit contains one share (or a pre-funded warrant) and one five-year common warrant.
The registration also covers 45,340 representative warrants and up to 1,556,674 shares issuable upon warrant exercise. Underwriters hold a 45-day option to purchase an additional 113,350 shares and/or warrants. The assumed public price matches the 25 Jun 2025 close of $7.94.
A 1-for-30 reverse stock split became effective 24 Jun 2025 to restore Nasdaq compliance. Proceeds, net of underwriting fees, are expected to fund operations; investors should review the Risk Factors section (p.17) for clinical, liquidity and dilution risks.
Cellectar Biosciences (Nasdaq: CLRB) filed an 8-K disclosing a one-for-thirty reverse stock split of its common stock, effective June 24 2025, through an amendment to its Second Amended and Restated Certificate of Incorporation.
No fractional shares will be issued; instead, all fractional interests will be aggregated, sold by the transfer agent at prevailing market prices, and net cash proceeds distributed pro-rata to affected holders. The action is reported under Item 3.03 (Material Modification to Rights of Security Holders) and Item 5.03 (Charter Amendment). Exhibit 3.1 contains the full amendment and Exhibit 104 provides the Inline XBRL cover page.
The filing, signed by CFO Chad J. Kolean on June 25 2025, materially alters the capital structure and share count for existing investors.
Cellectar Biosciences, Inc. (Nasdaq: CLRB) has filed a Form 8-K to disclose that its stockholders approved, and the board of directors has subsequently set, a one-for-thirty reverse stock split of the company’s common stock. The split will take effect at 12:01 a.m. ET on June 24, 2025 (the “Effective Time”).
At the Effective Time, every 30 shares of issued and outstanding common stock will be automatically combined into 1 share; fractional shares will be paid out in cash. The filing notes that the reverse split will proportionately adjust (i) the share reserves under all company equity-incentive plans, (ii) the share quantities and exercise or conversion prices of outstanding stock options and warrants, and (iii) the conversion ratios of any outstanding preferred stock, thereby keeping the aggregate economic value of each instrument unchanged.
The company attached a press release (Exhibit 99.1) titled “Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split” and an Inline XBRL cover page file (Exhibit 104). No other operational or financial data were provided in this filing.